Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypothyroxinemia induction in recurrent glioblastoma
NCT05017610Phase 1Withdrawn
- Sponsor
- Emory University
- Start
- Oct 2021
- Primary completion
- Oct 2022
01
Overview
Phase 1, open-label trial of methimazole in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Emory University. Planned start Oct 2021; status: withdrawn.
02
Drugs
methimazole
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT05017610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017610.